AbbVie's elagolix meets in second Phase III for uterine fibroids

AbbVie Inc. (NYSE:ABBV) said elagolix (ABT-620) met the primary and all ranked secondary endpoints in the Phase III ELARIS UF-II (M12-817) trial, the second of two replicate Phase III trials of the non-peptide small molecule gonadotropin-releasing hormone (GnRH) antagonist to treat uterine fibroids. AbbVie said a commercial launch of elagolix to treat uterine fibroids is planned for 2020, but the company declined to disclose a timeline for regulatory submissions.

In February, AbbVie said elagolix met the primary and all ranked secondary endpoints in the first trial, ELARIS UF-I (M12-815) (see BioCentury, Feb. 23)...